← brief for 2026-09-12 · Slowing decline

Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.

Key takeaways

This review explains how SGLT2 inhibitor drugs work inside the body, in people with diabetes and people without it. The drug acts on one small part of the kidney, the proximal tubule, where it blocks the reabsorption of sugar and salt so both leave in the urine. From there the effects spread to blood pressure, fluid balance and how the body uses fuel. The human studies behind it are small physiology studies, so they trace a chain of effects rather than prove that chain causes better outcomes.

Who did this work

Ferrannini E

Source

Article · PubMed, the drug frontier · 2026 Sep 13
https://pubmed.ncbi.nlm.nih.gov/42730799/